AstraZeneca’s COVID-19 vaccine begins phase 3

AstraZeneca, the biopharmaceutical company, said its COVID-19 vaccine AZD1222 expands into a phase 3 clinical trial in the U.S

Trader 2

AstraZeneca, the biopharmaceutical company, said its COVID-19 vaccine AZD1222 expands into a phase 3 clinical trial in the U.S., enrolling up to 30,000 adults. Meanwhile, the company reported that its Imfinzi has been approved in the European Union for the treatment of extensive-stage small cell lung cancer. Also, it said its Farxiga demonstrated unprecedented reduction in the risk of kidney failure and cardiovascular or renal death in patients with chronic kidney disease in the Phase 3 DAPA-CKD trial.


From a chartist’s point of view, the stock price has entered into a consolidation move and is capped by the key resistance threshold at 8811p. The 50-DMA started to flatten out indicating a lack of momentum in the short term. The Daily Relative Strength Index (RSI, 14) is capped by a declining trend line. Readers may want to consider opening Short positions below the key resistance level at 8811 with 8048p and 7685p as targets (congestion zone). Alternatively, a push above 8811p would open a path to see 9400p. 

Source: GAIN Capital, TradingView

Build your confidence risk free

More from Equities

Join our live webinars for the latest analysis and trading ideas. Register now

StoneX Financial Ltd (trading as “City Index”) is an execution-only service provider. This material, whether or not it states any opinions, is for general information purposes only and it does not take into account your personal circumstances or objectives. This material has been prepared using the thoughts and opinions of the author and these may change. However, City Index does not plan to provide further updates to any material once published and it is not under any obligation to keep this material up to date. This material is short term in nature and may only relate to facts and circumstances existing at a specific time or day. Nothing in this material is (or should be considered to be) financial, investment, legal, tax or other advice and no reliance should be placed on it.

No opinion given in this material constitutes a recommendation by City Index or the author that any particular investment, security, transaction or investment strategy is suitable for any specific person. The material has not been prepared in accordance with legal requirements designed to promote the independence of investment research. Although City Index is not specifically prevented from dealing before providing this material, City Index does not seek to take advantage of the material prior to its dissemination. This material is not intended for distribution to, or use by, any person in any country or jurisdiction where such distribution or use would be contrary to local law or regulation.

For further details see our full non-independent research disclaimer and quarterly summary.